Chelsea Payne, PA
Physician Assistant · Lodi, CANPI 1245852144
Payments from drug & device makers
Across 268 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$593
- GSK$535
- Novo Nordisk$519
- Boehringer Ingelheim$483
- AbbVie$448
- Bayer$292
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 36 | $593 |
| GSK | 25 | $535 |
| Novo Nordisk | 28 | $519 |
| Boehringer Ingelheim | 24 | $483 |
| AbbVie | 27 | $448 |
| Bayer | 13 | $292 |
| Johnson & Johnson | 17 | $270 |
| Biohaven Pharmaceuticals, Inc. | 9 | $162 |
| Merck | 8 | $158 |
| Eisai Inc. | 7 | $121 |
| Novartis | 6 | $111 |
| Esperion Therapeutics, Inc. | 5 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $83 |
| AstraZeneca | 4 | $76 |
| Pfizer | 3 | $76 |
| Gilead | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| IBSA Pharma Inc. | 4 | $64 |
| Exact Sciences | 3 | $58 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Therapeuticsmd, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Upsher-smith Laboratories LLC | 2 | $42 |
| Boston Scientific | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Mylan Inc. | 1 | $34 |
| Alfasigma USA, Inc. | 2 | $26 |
| Seqirus USA Inc | 1 | $19 |
| Globus Medical | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Organon | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Corcept Therapeutics | 1 | $13 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
How this compares
$4,970 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $48,964 |
| JardianceEmpagliflozin | 40 | $42,463 |
| MounjaroTirzepatide | 34 | $33,111 |
| XareltoRivaroxaban | 19 | $18,760 |
| TrulicityDulaglutide | 16 | $15,837 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,079 |
| VascepaIcosapent Ethyl | 12 | $5,866 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,745 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $2,402 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,947 |
| Atorvastatin Calcium | 171 | $1,305 |
| Metoprolol Succinate | 58 | $731 |
| Levothyroxine Sodium | 68 | $696 |
| Gabapentin | 60 | $677 |
| Losartan Potassium | 78 | $662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $48,96455 claims |
| Lilly USA, LLCMounjaro, Trulicity | $593 | $48,94850 claims |
| Boehringer IngelheimJardiance | $483 | $42,46340 claims |
| Johnson & JohnsonXarelto | $270 | $18,76019 claims |
| GSKBreo Ellipta | $535 | $4,74512 claims |
| Mylan Inc.Atorvastatin Calcium | $34 | $1,305171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Lodi
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.